American Journal of Cardiology
Volume 101, Issue 12, Supplement , Pages S23-S33 , 16 June 2008

Lipoprotein-Associated Phospholipase A2: An Independent Predictor of Coronary Artery Disease Events in Primary and Secondary Prevention

  • Jeffrey L. Anderson, MD

      Affiliations

    • Corresponding Author InformationAddress for reprints: Jeffrey L. Anderson, MD, Cardiovascular Department, LDS Hospital, University of Utah, 325 8th Avenue, Salt Lake City, Utah 84143.

References 

  1. Packard CJ, O'Reilly DSJ, Caslake MJ, McMahan AD, Ford I, Cooney J, et al. Lipoprotein-associated phospholipase A2 as an independent predictor of coronary heart disease. N Engl J Med. 2000;343:1148–1155
  2. Blake GJ, Dada N, Fox JC, Manson JE, Ridker PM. A prospective evaluation of lipoprotein-associated phospholipase A2 levels and the risk of future cardiovascular events in women. J Am Coll Cardiol. 2001;38:1302–1306
  3. Blankenberg S, Stengel D, Rupprecht HJ, Bickel C, Meyer J, Cambien F, et al. Plasma PAF-acetylhydrolase in patients with coronary artery disease: results of a cross-sectional analysis. J Lipid Res. 2003;44:1381–1386
  4. Ballantyne CM, Hoogeveen RC, Bang H, Coresh J, Folsom AR, Heiss G, et al. Lipoprotein-associated phospholipase A2, high-sensitivity C-reactive protein, and risk for incident heart disease in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) study. Circulation. 2004;109:837–842
  5. Koenig W, Khuseyinova N, Löwel H, Trischler G, Meisinger C. Lipoprotein-associated phospholipase A2 adds to risk prediction of incident coronary events by C-reactive protein in apparently healthy middle-aged men from the general population: results from the 14-year follow-up of a large cohort from southern Germany (MONICA-Augsburg). Circulation. 2004;110:1903–1908
  6. Winkler K, Abletshauser C, Friedrich I, Hoffmann MM, Wieland H, März W. Fluvastatin slow-release lowers platelet-activating factor acetyl hydrolase activity: a placebo-controlled trial in patients with type 2 diabetes. J Clin Endocrinol Metab. 2004;89:1153–1159
  7. Brilakis ES, McConnell JP, Lennon RJ, Elesber AA, Meyer JG, Berger PB. Association of lipoprotein-associated phospholipase A2 levels with coronary artery disease risk factors, angiographic coronary artery disease, and major adverse events at follow-up. Eur Heart J. 2005;26:137–144
  8. Oei H-HS, van der Meer IM, Hofman A, Koudstaal PJ, Stijnen T, Breteler MMB, et al. Lipoprotein-associated phospholipase A2 activity is associated with risk of coronary heart disease and ischemic stroke: the Rotterdam Study. Circulation. 2005;111:570–575
  9. Winkler K, Winkelmann BR, Scharnagl H, Hoffman MM, Grawitz AB, Nauck M, et al. Platelet-activating factor acetylhydrolase activity indicates angiographic coronary artery disease independently of systemic inflammation and other risk factors. Circulation. 2005;111:980–987
  10. Khuseyinova N, Imhof A, Rothenbacher D, Trischler G, Kuelb S, Scharnagl H, et al. Association between Lp-PLA2 and coronary artery disease: focus on its relationship with lipoproteins and markers of inflammation and hemostasis (HELICOR). Atherosclerosis. 2005;182:181–188
  11. Koenig W, Twardella D, Brenner H, Rothenbacher D. Lipoprotein-associated phospholipase A2 predicts future cardiovascular events in patients with coronary heart disease independently of traditional risk factors, markers of inflammation, renal function and hemodynamic stress (KAROLA). Arterioscler Thromb Vasc Biol. 2006;26:1586–1593
  12. May HT, Horne BD, Anderson JL, Wolfert RL, Muhlestein JB, Renlund DG, et al. Lipoprotein-associated phospholipase A2 independently predicts the angiographic diagnosis of coronary artery disease and coronary death. Am Heart J. 2006;152:997–1003
  13. Caslake MJ, Cooney J, Murray E, Bedford D, Robertson M, Nelson JJ, Packard CJ. Lipoprotein-associated phospholipase A2 as a risk factor for coronary vascular disease in the elderly (PROSPER). Proceedings from the XIV International Symposium on Atherosclerosis; June 18–22, 2006; Rome, Italy. Abstract page 484.
  14. Jenny NS, Solomon C, Cushman M, Nelson JJ, Tracy RP, Psaty BM, et al. Lipoprotein-associated phospholipase A2 and cardiovascular disease: results from the Cardiovascular Health Study [abstract]. Circulation. 2006;113:E-332
  15. Daniels LB, Barrett-Connor E, Sarno M, Laughlin GA, Bettencourt R, Wolfert RL. Lipoprotein-associated phospholipase A2 (Lp-PLA2) independently predicts incident coronary heart disease (CHD) in an apparently healthy older population: the Rancho Bernardo Study [abstract]. Circulation. 2006;114:II-870
  16. O'Donoghue M, Morrow DA, Sabatine MS, Murphy SA, McCabe CH, Cannon CP, et al. Lp-PLA2 and its association with cardiovascular outcomes in patients with acute coronary syndromes in the PROVE IT–TIMI 22 (PRavastatin Or atorVastatin Evaluation and Infection-Thrombolysis in Myocardial Infarction) trial. Circulation. 2006;113:1745–1752
  17. Corsetti JP, Rainwater DL, Moss AJ, Zareba W, Sparks CE. High lipoprotein-associated phospholipase A2 is a risk factor for recurrent coronary events in postinfarction patients. Clin Chem. 2006;52:1331–1338
  18. Gerber Y, McConnell JP, Jaffe AS, Weston SA, Killian JM, Roger VL. Lipoprotein-associated phospholipase A2 and prognosis after myocardial infarction in the community. Arterioscler Thromb Vasc Biol. 2006;26:2517–2522
  19. Sabatine MS, Morrow DA, O'Donoghue M, Jablonski KA, Rice MM, Solomon S, et al. Prognostic utility of lipoprotein-associated phospholipase A2 for cardiovascular outcomes in patients with stable coronary artery disease. Arterioscler Thromb Vasc Biol. 2007;27:2463–2469
  20. Robins SJ, Collins D, Nelson JJ, Bloomfield HE, Asztalos BF. Cardiovascular events with increased lipoprotein-associated phospholipase A2 and low high-density lipoprotein-cholesterol (The Veterans Affairs HDL Intervention Trial). Arterioscler Thromb Vasc Biol. 2008;28:DOI: 10.1161/ATVBAHA.107.160739
  21. Oldgren J, James SK, Siegbahn A, Wallentin L. Lipoprotein-associated phospholipase A2 does not predict mortality or new ischaemic events in acute coronary syndrome patients. Eur Heart J. 2007;28:699–704
  22. Mockel M, Muller R, Vollert JO, Muller C, Danne O, Gareis R, et al. Lipoprotein-associated phospholipase A2 for early risk stratification in patients with suspected acute coronary syndrome: a multi-marker approach: the North Wuerttemberg and Berlin Infarction Study-II (NOBIS-II). Clin Res Cardiol. 2007;96:604–612
  23. Kiechl S, Willeit J, Mayr M, Viehweider B, Oberhollenzer M, Kronenberg F, et al. Oxidized phospholipids, lipoprotein(a), lipoprotein-associated phospholipase A2 activity, and 10-year cardiovascular outcomes: prospective results from the Bruneck study. Arterioscler Thromb Vasc Biol. 2007;27:1788–1795
  24. Persson M, Hedblad B, Nelson JJ, Berglund G. MALMO elevated Lp-PLA2 levels add prognostic information to the metabolic syndrome on incidence of cardiovascular events among middle-aged nondiabetic subjects. Arterioscler Thromb Vasc Biol. 2007;27:1411–1416
  25. Hatoum IJ, Nelson JJ, Rexrode K, Manson J, Rimm EB. Lipoprotein-associated phospholipase A2 and myocardial infarction in women. Circulation. 2007;116:II-818;Abstract 3605
  26. McConnell JP, Hoefner DA. Lipoprotein-associated phospholipase A2. J Clin Lab Med. 2006;26:679–697
  27. Ballantyne CM, Hoogeveen RC, Bang H, Coresh J, Folsom AR, Chambless LE, et al. Lipoprotein-associated phospholipase A2, high-sensitivity C-reactive protein, and risk for incident ischemic stroke in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) study. Arch Intern Med. 2005;165:2479–2484
  28. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 2001;285:2486–2497
  29. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002;106:II-30–II-31
  30. Pearson TA, Mensah GA, Alexander RW, Anderson JL, Cannon RO, Criqui M, et al Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation. 2003;107:499–511
  31. Greenland P, Smith SC, Grundy SM. Improving coronary disease risk assessment in asymptomatic people: role of traditional risk factors and noninvasive cardiovascular tests. Circulation. 2001;104:1863–1867
  32. Deedwania PC, Maki KC, Dicklin MR, Stone NJ, Ballantyne CM, Davidson MH. Application of recent definitions of the metabolic syndrome to survey data from the National Cholesterol Education Program Evaluation Project Utilizing Novel E-Technology (NEPTUNE II). J Cardiometab Syndr. 2006;1:295–300
  33. Hu FB, Stampfer MJ, Haffner SM, Solomon CG, Willett WC, Manson JE. Elevated risk of cardiovascular disease prior to clinical diagnosis of type 2 diabetes. Diabetes Care. 2002;25:1129–1134
  34. McLaughlin TM, Abbasi F, Wolfert R, Lamendola C, Reaven G, Reaven P. Lipoprotein-associated phospholipase A2 is not increased in association with insulin resistance [abstract]. Arterioscler Thromb Vasc Biol. 2004;24:E-67
  35. Carlquist JF, Muhlestein JB, Anderson JL. Lipoprotein-associated phospholipase A2: a new biomarker for cardiovascular risk assessment and potential therapeutic target. Expert Rev Mol Diagn. 2007;7:511–517
  36. Smith SC, Allen J, Blair SN, Bonow RO, Brass LM, Fonarow GC, et al AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update. Circulation. 2006;113:2363–2372
  37. Grundy SM, Cleeman JI, Merz CN, Brewer HB, Clark LT, Hunninghake DB, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation. 2004;110:227–239
  38. Cannon CP, Braunwald E, McCabe CH, Rader DJ, Rouleau JL, Belder R, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med. 2004;350:1495–1504
  39. Ridker PM, Cannon CP, Morrow D, Rifai N, McCabe CH, Pfeffer MA, et al. C-reactive protein levels and outcomes after statin therapy. N Engl J Med. 2005;352:20–28
  40. Bogaty P, Brophy JM, Boyer L, Simard S, Joseph L, Bertrand F, et al. Fluctuating inflammatory markers in patients with stable ischemic heart disease. Arch Intern Med. 2005;165:221–226
  41. Khor LL, Muhlestein JB, Carlquist JF, Horne BD, Bair TL, Maycock CA, et al. Sex- and age-related differences in the prognostic value of C-reactive protein in patients with angiographic coronary artery disease. Am J Med. 2004;117:657–664
  42. Winkler K, Hoffmann MM, Winkelmann BR, Friedrich I, Schafer G, Seelhorst U, et al. Lipoprotein-associated phospholipase A2 predicts 5-year mortality independently of established risk factors and adds prognostic information in patients with low and medium high-sensitivity C-reactive protein (the Ludwigshafen Risk and Cardiovascular Health Study). Clin Chem. 2007;53:1440–1447
  43. Khuseyinova N, Greven S, Rueckerl R, Trischler G, Loewel H, Peters A, et al. Variability of serial Lp-PLA2 measurements in post-myocardial infarction patients: results from the AIRGENE Study Center Augsburg. Clin Chem. 2007;54:124–130

 Statement of author disclosure: Please see the Author Disclosures section at the end of this article.

PII: S0002-9149(08)00686-3

doi: 10.1016/j.amjcard.2008.04.015

American Journal of Cardiology
Volume 101, Issue 12, Supplement , Pages S23-S33 , 16 June 2008

Article Tools

* Image Usage & Resolution